MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.12.24

MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.12.24 Stock

DE000MB0BQN9

Market Closed - Börse Stuttgart 14:19:38 2024-07-05 EDT
0.43 ^EUR	+7.50%

Current month	-8.51%
1 month	-6.52%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart MORGAN STANLEY PLC/CALL/AMGEN/400/0.1/20.12.24

Latest news about AMGEN INC.

Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints	07-02	MT
Amgen Inc.(NasdaqGS:AMGN) added to Russell 1000 Dynamic Index	06-30	CI
Argus Raises Amgen's Price Target to $340 From $300	06-27	MT
Amgen CEO Bob Bradway’s Advice to Amgen’s Summer Interns: Don’t Hold Back	06-27	PU

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.43	+7.50%
24-07-04	0.4	0.00%
24-07-03	0.4	-11.11%
24-07-02	0.45	-2.17%
24-07-01	0.46	-2.13%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:19 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Morgan Stanley
WKN	MB0BQN
ISIN	DE000MB0BQN9
Date issued	2022-11-09
Strike	400 $
Maturity	2024-12-20 (167 Days)
Parity	10 : 1
Emission price	1.33 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.69 €
Lowest since issue	0.13 €
Delta	0.15x
Omega	9.719
Premium	30.25x
Gearing	63.04x
Moneyness	0.7772
Difference Strike	89.12 $
Difference Strike %	+22.28%
Spread	0.03 €
Spread %	6.38%
Theoretical value	0.4550
Implied Volatility	31.85 %
Total Loss Probability	88.99 %
Intrinsic value	0.000000
Present value	0.4550
Break even	404.93 €
Theta	-0.03x
Vega	0.05x
Rho	0.02x

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

310.9 USD

Average target price

316.4 USD

Spread / Average Target

+1.79%

Consensus